Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2014 1
2017 1
2019 1
2020 2
2021 2
2022 8
2023 7
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.
Pavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K, Daizadeh N, Ortiz B, Johnson RR, Harel S, Djandji M, Goga L, Crikelair N, Rowe PJ, Busse WW. Pavord ID, et al. Among authors: djandji m. J Allergy Clin Immunol Pract. 2023 Apr;11(4):1213-1220.e2. doi: 10.1016/j.jaip.2022.11.043. Epub 2022 Dec 16. J Allergy Clin Immunol Pract. 2023. PMID: 36535524 Free article. Clinical Trial.
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD.
Rabe KF, Martinez FJ, Bhatt SP, Kawayama T, Cosio BG, Mroz RM, Boomsma MM, Goulaouic H, Nivens MC, Djandji M, Soler X, Liu Y, Kosloski MP, Xu CR, Amin N, Staudinger H, Lederer DJ, Abdulai RM. Rabe KF, et al. Among authors: djandji m. ERJ Open Res. 2024 Sep 23;10(5):00718-2023. doi: 10.1183/23120541.00718-2023. eCollection 2024 Sep. ERJ Open Res. 2024. PMID: 39319046 Free PMC article.
The emerging role of alarmin-targeting biologics in the treatment of patients with COPD.
Celli BR, Anzueto A, Singh D, Hanania NA, Fabbri L, Martinez FJ, Soler X, Djandji M, Jacob-Nara JA, Rowe PJ, Deniz Y, Radwan A. Celli BR, et al. Among authors: djandji m. Chest. 2024 Dec 2:S0012-3692(24)05602-2. doi: 10.1016/j.chest.2024.09.049. Online ahead of print. Chest. 2024. PMID: 39631681 Free article. Review.
Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.
Brusselle G, Quirce S, Papi A, Kuna P, Chipps BE, Hanania NA, Blaiss M, Msihid J, Jacob-Nara JA, Deniz Y, Rowe PJ, Gall R, Ortiz B, Djandji M, Radwan A. Brusselle G, et al. Among authors: djandji m. J Allergy Clin Immunol Pract. 2023 Mar;11(3):873-884.e11. doi: 10.1016/j.jaip.2022.11.044. Epub 2022 Dec 23. J Allergy Clin Immunol Pract. 2023. PMID: 36572184 Free article.
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases.
Canonica GW, Bourdin A, Peters AT, Desrosiers M, Bachert C, Weidinger S, Simpson EL, Daizadeh N, Chen Z, Kamat S, Khan AH, Chao J, Graham NMH, Laws E, Rossi AB, Ardeleanu M, Mannent LP, Amin N, Ortiz B, Deniz Y, Djandji M, Rowe PJ. Canonica GW, et al. Among authors: djandji m. J Allergy Clin Immunol Pract. 2022 Jun;10(6):1515-1526. doi: 10.1016/j.jaip.2022.02.026. Epub 2022 Mar 6. J Allergy Clin Immunol Pract. 2022. PMID: 35259535 Free article. Clinical Trial.
Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study.
Maspero JF, Cardona G, Schonffeldt P, Tolcachier A, González-Diaz SN, Yañez A, Galvao CE, Msihid J, Gall R, Siddiqui S, Rowe PJ, Deniz Y, Jacob-Nara JA, Djandji M. Maspero JF, et al. Among authors: djandji m. J Asthma. 2023 May;60(5):981-990. doi: 10.1080/02770903.2022.2115927. Epub 2022 Oct 17. J Asthma. 2023. PMID: 36066123 Free article. Clinical Trial.
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.
Papadopoulos NG, Szefler SJ, Bacharier LB, Maspero JF, Domingo C, Fiocchi A, Lee JK, Daizadeh N, Lederer DJ, Hardin M, Gall R, Djandji M, Siddiqui S, Jacob-Nara JA, Deniz Y, Rowe PJ. Papadopoulos NG, et al. Among authors: djandji m. Allergy. 2023 Aug;78(8):2157-2167. doi: 10.1111/all.15743. Epub 2023 May 25. Allergy. 2023. PMID: 37059696
Rhinology Future Debates, an EUFOREA Report.
Fokkens WJ, Bachert C, Bernal-Sprekelsen M, Bousquet J, Djandji M, Dorenbaum A, Hakimi-Mehr D, Hendry S, Hopkins C, Leunig A, Mannent L, Mucha D, Onerci M, Pugin B, Toppila-Salmi S, Rowe P, Seys SF, Stimson S, Strzembosz A, Hellings PW. Fokkens WJ, et al. Among authors: djandji m. Rhinology. 2017 Dec 1;55(4):298-304. doi: 10.4193/Rhin17.221. Rhinology. 2017. PMID: 29166426
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study.
Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Msihid J, Djandji M, Ortiz B, Jacob-Nara JA, Deniz Y, Rowe PJ, Ishida M, Arima K. Tohda Y, et al. Among authors: djandji m. Allergol Int. 2023 Jan;72(1):89-99. doi: 10.1016/j.alit.2022.07.008. Epub 2022 Sep 13. Allergol Int. 2023. PMID: 36114102 Free article.
21 results